Last reviewed · How we verify
Remimazolam Tosilate
At a glance
| Generic name | Remimazolam Tosilate |
|---|---|
| Also known as | Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China), experimental |
| Sponsor | Harbin Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients (NA)
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
- A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients (PHASE2, PHASE3)
- A Study of Remimazolam Tosilate for Sedation in the ICU (PHASE3)
- A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy
- A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
- A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU (PHASE1, PHASE2)
- Impact of Remimazolam on Prognosis After Bladder Cancer Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remimazolam Tosilate CI brief — competitive landscape report
- Remimazolam Tosilate updates RSS · CI watch RSS
- Harbin Medical University portfolio CI